PDCD1 and progressive multifocal leukoencephalopathy: For example, Hoang et al50 described a biopsy-confirmed PML case in which the PD-1 inhibitor nivolumab seems to have stimulated immune activation resulting in effective disease control in the patient with a concomitant hematological malignancy.50–52